Clinical Trial Update: A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase II study assessing RBM-007 alone and with Eylea in wet age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• RBM-007

Snippet

Sponsor: Ribomic USA Inc | Conditions: Exudative Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2023-06-08